{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T07:33:34Z","timestamp":1790408014293,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2006,3,16]],"date-time":"2006-03-16T00:00:00Z","timestamp":1142467200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2006,5,22]]},"DOI":"10.1007\/s11060-005-9070-4","type":"journal-article","created":{"date-parts":[[2006,3,15]],"date-time":"2006-03-15T14:21:52Z","timestamp":1142432512000},"page":"99-102","source":"Crossref","is-referenced-by-count":99,"title":["Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumor patients"],"prefix":"10.1007","volume":"78","author":[{"given":"Herbert B.","family":"Newton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel A.","family":"Goldlust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Pearl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,3,16]]},"reference":[{"key":"9070_CR1","first-page":"787","volume":"49","author":"HB Newton","year":"1994","unstructured":"Newton HB, 1994 Primary brain tumors: Review of etiology, diagnosis, and treatment Am Fam Phys 49: 787\u2013797","journal-title":"Am Fam Phys"},{"key":"9070_CR2","first-page":"878","volume":"59","author":"HB Newton","year":"1999","unstructured":"Newton HB, 1999 Neurological complications of systemic cancer Am Fam Phys 59: 878\u2013886","journal-title":"Am Fam Phys"},{"key":"9070_CR3","first-page":"9","volume-title":"Handbook of Clinical Neurology","author":"M Glantz","year":"1997","unstructured":"Glantz M, Recht LD, 1997 Epilepsy in the cancer patient. In: Vecht C.J., (ed.) Handbook of Clinical Neurology Vol. 25 Elsevier Science Amsterdam, pp 9\u201318"},{"key":"9070_CR4","first-page":"S27","volume":"1","author":"EB Bromfield","year":"2004","unstructured":"Bromfield EB, 2004 Epilepsy in patients with brain tumors and other cancers Rev Neurol Dis 1: S27\u2013S33","journal-title":"Rev Neurol Dis"},{"key":"9070_CR5","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1046\/j.1528-1157.2003.05203.x","volume":"44","author":"B Schaller","year":"2003","unstructured":"Schaller B, Ruegg SJ, 2003 Brain tumor and seizures: pathophysiology and its implications for treatment revisited Epilepsia 44: 1223\u20131232","journal-title":"Epilepsia"},{"key":"9070_CR6","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/00001622-200009000-00011","volume":"12","author":"B Tan","year":"2000","unstructured":"Tan B, Piwinica-Worms D, Ratner L, 2000 Multidrug resistance transporters and modulation Curr Opin Oncol 12: 450\u2013458","journal-title":"Curr Opin Oncol"},{"key":"9070_CR7","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1212\/01.WNL.0000123693.82339.FC","volume":"62","author":"JA French","year":"2004a","unstructured":"French JA, Kanner AM, Bautista J, et al 2004a Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy Neurol 62: 1252\u20131260","journal-title":"Neurol"},{"key":"9070_CR8","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1212\/01.WNL.0000123695.22623.32","volume":"62","author":"JA French","year":"2004b","unstructured":"French JA, Kanner AM, Bautista J, et al 2004b Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy Neurol. 62: 1261\u20131273","journal-title":"Neurol."},{"key":"9070_CR9","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0163-7258(99)00052-2","volume":"85","author":"PN Patsalos","year":"2000","unstructured":"Patsalos PN, 2000 Pharmacokinetic profile of levetiracetam: toward ideal characteristics Pharmacol Ther 85: 77\u201385","journal-title":"Pharmacol Ther"},{"key":"9070_CR10","doi-asserted-by":"crossref","first-page":"9861","DOI":"10.1073\/pnas.0308208101","volume":"101","author":"BA Lynch","year":"2004","unstructured":"Lynch BA, Lambeng N, Nocka K, et al 2004 The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam Proc Natl Acad Sci 101: 9861\u20139866","journal-title":"Proc Natl Acad Sci"},{"key":"9070_CR11","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1528-1157.2000.tb02945.x","volume":"41","author":"I Niespodziany","year":"2000","unstructured":"Niespodziany I, Klitgaard H, Margineanu DG, 2000 Levetiracetam: modulation of high voltage activated Ca++ current in CA1 pyramidal neurons of rat hippocampal slices (abstract) Epilepsia 41: 37","journal-title":"Epilepsia"},{"key":"9070_CR12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1528-1157.2002.24501.x","volume":"43","author":"EA Lukyanetz","year":"2002","unstructured":"Lukyanetz EA, Shkryl VM, Kostyuk PG, 2002 Selective blockade of N-type calcium channels by levetiracetam Epilepsia 43:9\u201318","journal-title":"Epilepsia"},{"key":"9070_CR13","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1053\/seiz.2000.0504","volume":"10","author":"C Zona","year":"2001","unstructured":"Zona C, Niespodziany I, Marchetti C, Klitgaard H, Bernardi G, Margineanu DG, 2001 Levetiracetam does not modulate neuronal voltage-gated Na+ and T-type Ca++ currents Seizure 10: 279\u2013286","journal-title":"Seizure"},{"key":"9070_CR14","first-page":"59","volume":"136","author":"JM Rigo","year":"2002","unstructured":"Rigo JM, Hans G, Nguyen L, et al, 2002 The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine -gated currents Br J Pharmacol 136: 59\u2013672","journal-title":"Br J Pharmacol"},{"key":"9070_CR15","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S1059-1311(03)00096-7","volume":"12","author":"GL Wagner","year":"2003","unstructured":"Wagner GL, Wilms EB, Van Donselaar CA, Vecht CJ, 2003 Levetiracetam: preliminary experience in patients with primary brain tumors Seizure 12: 585\u2013586","journal-title":"Seizure"},{"key":"9070_CR16","first-page":"149","volume-title":"The Practical Management of Low-Grade Primary Brain Tumors","author":"K Elisevich","year":"1999","unstructured":"Elisevich K, 1999 Epilepsy and low-grade gliomas. In: Rock JP, Rosenblum ML, Shaw EG, Cairncross JG, (eds.), The Practical Management of Low-Grade Primary Brain Tumors Vol. 10 Lippincott Williams & Wilkins Philadelphia, pp 149\u2013169"},{"key":"9070_CR17","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.seizure.2004.12.006","volume":"14","author":"TM Alsaadi","year":"2005","unstructured":"Alsaadi TM, Shatzel A, Marquez AV, Jorgensen J, Farias S, 2005 Clinical experience of levetiracetam monotherapy for adults with epilepsy: 1-year follow-up study Seizure 14: 139\u2013142","journal-title":"Seizure"},{"key":"9070_CR18","first-page":"121","volume":"12","author":"F Habetswallner","year":"2005","unstructured":"Habetswallner F, Fels A, Pagliuca M, De Joanna G, Rossi V, Tessitore A, 2005 Levetiracetam as monotherapy for partial epilepsy in adults: A case series (abstract) Eur J Neurol 12: 121\u2013122","journal-title":"Eur J Neurol"},{"key":"9070_CR19","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1365-2125.1995.tb05796.x","volume":"40","author":"KT Kivisto","year":"1995","unstructured":"Kivisto KT, Kroemer HK, Eichelbaum M, 1995 The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions Br J Clin Pharmacol 40: 523\u2013530","journal-title":"Br J Clin Pharmacol"},{"key":"9070_CR20","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1053\/j.seminoncol.2003.11.030","volume":"30","author":"CJ Vecht","year":"2003a","unstructured":"Vecht CJ, Wagner GL, Wilms EB, 2003a Treating seizures in patients with brain tumors: drug interactions between antiepileptic and chemotherapeutic agents Semin Oncol 30: 49\u201352","journal-title":"Semin Oncol"},{"key":"9070_CR21","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S1474-4422(03)00435-6","volume":"2","author":"CJ Vecht","year":"2003b","unstructured":"Vecht CJ, Wagner GL, Wilms EB, 2003b Interactions between antiepileptic and chemotherapeutic drugs Lancet Neurol 2: 404\u2013409","journal-title":"Lancet Neurol"},{"key":"9070_CR22","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.1997.15.9.3121","volume":"15","author":"MR Fetell","year":"1997","unstructured":"Fetell MR, Grossman SA, Fisher JD, et al 1997 Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions J Clin Oncol 15: 3121\u20133128","journal-title":"J Clin Oncol"},{"key":"9070_CR23","first-page":"589","volume":"66","author":"K Villikka","year":"1999","unstructured":"Villikka K, Kivisto KT, Maenpaa H, Joensuu H, Neuvonen PJ, 1999 Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors Clin Pharmacol Ther 66: 589\u2013593","journal-title":"Clin Pharmacol Ther"},{"key":"9070_CR24","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1023\/A:1006404825356","volume":"48","author":"M Riva","year":"2000","unstructured":"Riva M, Landonio G, Defanti CA, Siena S, 2000 The effect of anticonvulsant drugs on blood levels of methotrexate J Neuro-Oncol 48: 249\u2013250","journal-title":"J Neuro-Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-005-9070-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-005-9070-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-005-9070-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T04:18:52Z","timestamp":1559362732000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-005-9070-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3,16]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,5,22]]}},"alternative-id":["9070"],"URL":"https:\/\/doi.org\/10.1007\/s11060-005-9070-4","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,3,16]]}}}